Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery
Authors:
- Tracy M. DownsTDTracy M. Downs
- Howard H. BaileyHBHoward H. Bailey
- Taja LozarTLTaja Lozar
- Natalie S. SchmitzNSNatalie S. Schmitz
- Heather GreenHGHeather Green
- Cameron O. ScarlettCSCameron O. Scarlett
- Thomas C. HavighurstTHThomas C. Havighurst
- Kyleigh TwaroskiKTKyleigh Twaroski
- Katina DeShongKDKatina DeShong
- Barbara WollmerBWBarbara Wollmer
- Trinity J. BivalacquaTBTrinity J. Bivalacqua
- Daniel R. SaltzsteinDSDaniel R. Saltzstein
- 27 August 2024
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 18 (1) , 31-39
Abstract
We performed a clinical trial in patients with non–muscle-invasive (NMI) urothelial cancer randomized (2:1) to the EGFR tyrosine kinase inhibitor erlotinib or placebo (either orally once weekly × 3 doses prior to scheduled surgery) to assess for a difference in EGFR phosphorylation in tumor-adjacent normal urothelium <24 hours post–study dose and tolerance of weekly erlotinib therapy. Thirty-seven volunteers (6 female/31 male; mean age 70; 35 White/2 non-White) with confirmed or suspected NMI urothelial cancer were enrolled into either erlotinib (n = 24; 900 mg-13, 600 mg-11) or placebo (n = 13). IHC assessment of phosphorylated and total EGFR in tumor-adjacent normal urothelium (20 erlotinib and 9 placebo subjects) or tumor (21 erlotinib and 11 placebo subjects) at study end showed no significant difference between those receiving erlotinib or placebo. This was also true for other assessed tissue biomarkers (phosphorylated ERK, ERK, E-cadherin, p53, and Ki67). Adverse events were more common, in a dose-related fashion, in participants receiving erlotinib, e.g., 38% experienced grade 1 with rare grade 2 diarrhea and skin toxicity versus 8% in placebo. Clinically insignificant but statistically significant (P = 0.001) elevations in serum total bilirubin and creatinine were observed in participants receiving erlotinib. Serum erlotinib and metabolite concentrations (OSI-420) confirmed compliance in all subjects receiving erlotinib and did not significantly differ between the 600 and 900 mg doses. Despite compelling preclinical and clinical data for targeted EGFR inhibition in bladder cancer prevention, these data do not support the use of weekly erlotinib therapy to prevent progression of NMI bladder cancer. Prevention Relevance: We evaluated the potential of erlotinib in preventing cancer by performing a randomized, double-blind, placebo-controlled trial of weekly erlotinib therapy in participants undergoing surgical removal of suspected noninvasive bladder neoplasia. Weekly erlotinib therapy was tolerated with common grade 1 to 2 toxicities but without evidence of beneficial effect upon urothelial tissue. See related Spotlight, p. 7Keywords
Funding Information
- National Cancer Institute (N01 CN05014)
- National Cancer Institute (UG1CA242635)
- National Cancer Institute (P30 CAO14520)
- National Institutes of Health (M01 RR03186)
This publication has 37 references indexed in Scilit:
- Bladder CancerJAMA, 2020
- Population Pharmacokinetics of Erlotinib in Patients With Non–small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older PatientsClinical Therapeutics, 2020
- Expression and Localization of DDX3 in Prostate Cancer Progression and MetastasisThe American Journal of Pathology, 2019
- Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical UseEBioMedicine, 2016
- Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non–small cell lung cancerClinical Pharmacology & Therapeutics, 2006
- A phase I/II study of weekly high‐dose erlotinib in previously treated patients with nonsmall cell lung cancerCancer, 2006
- Expression and functions of EGF FGF and TGFβ-growth-factor family members and their receptors in invasive human transitional-cell-carcinoma cellsInternational Journal of Cancer, 1997
- Superficial bladder cancer: state of the artCancer Chemotherapy and Pharmacology, 1994
- Bladder caner from a perspective of 40 yearsJournal of Cellular Biochemistry, 1992
- The epidermal growth factor receptor and the prognosis of bladder cancerCancer, 1990